Does Macrobid Cover Staph?
Yes, Macrobid (nitrofurantoin) does cover certain Staphylococcus species, specifically Staphylococcus saprophyticus and other coagulase-negative staphylococci, but it is FDA-approved only for treating uncomplicated urinary tract infections (UTIs), not systemic or skin/soft tissue staphylococcal infections. 1
FDA-Approved Coverage
According to the FDA drug label, Macrobid is indicated for acute uncomplicated cystitis caused by:
- Escherichia coli (primary pathogen)
- Staphylococcus saprophyticus 1
The label explicitly states that nitrofurantoin achieves therapeutic concentrations only in urine, not in broader tissue distribution, which severely limits its clinical utility for staph infections outside the urinary tract 1.
Extended In Vitro Activity
While FDA approval is limited to S. saprophyticus, the drug label notes that at least 90% of the following staphylococcal species demonstrate in vitro susceptibility (though clinical efficacy is not established in controlled trials):
- Coagulase-negative staphylococci (including S. epidermidis)
- Staphylococcus aureus 1
Research confirms 100% of staphylococcal strains tested show sensitivity to nitrofurantoin 2, and studies demonstrate effectiveness against both MRSA and MSSA in laboratory settings 3, 4.
Critical Clinical Limitations
Do not use Macrobid for:
- Skin and soft tissue staph infections
- Bacteremia or systemic staph infections
- Pyelonephritis or complicated UTIs
- Any infection requiring systemic antibiotic tissue penetration
The drug's mechanism concentrates it in urine but provides minimal systemic distribution 1. Even though nitrofurantoin shows excellent in vitro activity against S. aureus (including MRSA), this does not translate to clinical efficacy for non-urinary infections 3, 5.
Guideline-Supported Use
Current UTI guidelines recommend nitrofurantoin as first-line therapy for uncomplicated cystitis due to its narrow spectrum (E. coli and S. saprophyticus), minimal collateral damage to microbiota, and stable low resistance rates over 50+ years 6. The recommended dosing is 100 mg twice daily for 5 days 7, 6.
Bottom Line
Nitrofurantoin covers staphylococci microbiologically but is clinically appropriate only for uncomplicated UTIs caused by S. saprophyticus. For any other staphylococcal infection—including MRSA skin infections, bacteremia, or complicated UTIs—select antibiotics with appropriate tissue distribution such as vancomycin, linezolid, or trimethoprim-sulfamethoxazole 3.